AngioDynamics (ANGO, Financial), a leading medical device company, has seen a positive revision in its stock forecast as analyst William Plovanic from Canaccord Genuity increases the price target. The new price target has been set at USD 17.00, up from the previous target of USD 15.00.
The updated price target represents a 13.33% increase from the prior target. This adjustment underscores the analyst's continuing confidence in AngioDynamics' (ANGO, Financial) performance and future potential.
Canaccord Genuity maintains its "Buy" rating for AngioDynamics (ANGO, Financial), aligning with the analyst's optimistic outlook. The rating has remained unchanged, reinforcing the positive sentiment surrounding the company's growth trajectory.
The announcement was made on July 16, 2025, further highlighting the analyst's favorable view of AngioDynamics' (ANGO, Financial) positioning and opportunities in the medical device industry.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for AngioDynamics Inc (ANGO, Financial) is $15.67 with a high estimate of $16.00 and a low estimate of $15.00. The average target implies an upside of 81.12% from the current price of $8.65. More detailed estimate data can be found on the AngioDynamics Inc (ANGO) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, AngioDynamics Inc's (ANGO, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AngioDynamics Inc (ANGO, Financial) in one year is $8.26, suggesting a downside of 4.51% from the current price of $8.65. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AngioDynamics Inc (ANGO) Summary page.
